Aakash Desai: Biomarker Landscape of ADCs and Bispecifics in lung cancer Clinical Trials
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
“Out now in Clinical Lung Cancer, just in time for Lung Cancer Awareness Month!
Our article delves into the “Biomarker Landscape of ADCs and Bispecifics in Clinical Trials for lung cancer.”
Authors: Madhan Srinivasan Kumar, Sameer Deshmukh, Charmi Bhanushali, Yanis Boumber, Johnathan Riess, Abdul Rafeh Naqash, Vivek Subbiah,
Are we fully leveraging a biomarker-driven approach for these groundbreaking agents?
Our findings:
69.6% of ongoing clinical trials are centered on bispecific antibodies (bsAbs) while 30.4% on antibody-drug conjugates (ADCs)
Yet, only 47.8% employ biomarker testing like NGS & IHC
Key targets: EGFR x c-MET and PD-1 x CTLA-4 for bsAbs
TROP2 and HER2 for ADCs with most common payloads include topoisomerase inhibitors and monomethyl auristatin E.
Looking ahead:
It’s imperative that future trials integrate prospective biomarker strategies to propel personalized therapies forward.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023